CELC
$114.11
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Intraday
Recent News
What Celcuity (CELC)'s Gedatolisib Phase 3 Progression-Free Survival Data Means For Shareholders
Celcuity recently reported in the Journal of Clinical Oncology that its Phase 3 VIKTORIA-1 trial in PIK3CA wild-type HR-positive, HER2-negative advanced breast cancer showed gedatolisib-based regimens meaningfully extended progression-free survival versus fulvestrant alone. The data highlight gedatolisib’s differentiated pan-PI3K/mTORC1/2 mechanism, which aims to fully block PAM pathway signaling and limit adaptive resistance seen with single-target inhibitors. We’ll now examine how this...
Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference
Celcuity (NASDAQ:CELC) Chief Executive Officer Brian Sullivan outlined the company’s clinical and commercial priorities for its lead asset, gedatolisib, during a presentation at Leerink Partners’ Global Healthcare Conference. Sullivan said the company originally began as a platform effort focused on
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.